MHRA (UK)Original article
Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/39
RegulatoryMeropenem 1000 mg powder and solvent for solution for infusionNegative
AI Analysis
Summary
B. Braun Melsungen AG notified the MHRA of Patient Information Leaflet errors in batches of Meropenem 1000 mg powder and solvent for solution for infusion, classified as a Class 4 defect. The notification indicates a quality/labeling issue requiring regulatory attention but does not involve clinical trial data or market-moving decisions.
Outcome Details
Patient Information Leaflet errors identified in some batches; Class 4 defect notification issued
Importance:4/10
Sentiment:
-0.60
regulatory_defectpatient_safetyproduct_qualityPIL_errorMHRA_notification
Read the original article
Published by MHRA (UK) on September 23, 2026 1:00 PM